L-Lactic Acid

L-Lactic Acid

SCHEMBL407161

CC(O)C(=O)[O-].CC(O)C(=O)[O-].O.[Ca+2]

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3

The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
CA1 P00915 4/20 0.38
CA4 P22748 3/20 0.36
CA2 P00918 1/20 0.36
CYP3A4 P08684 2/20 0.35
TSHR P16473 2/20 0.35
NFKB1 P19838 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Lactic Acid SCHEMBL29543519 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL109735 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL9770204 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL145053 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL4737418 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL4648043 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL29683322 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL29351424 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL4319 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL1532627 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3756642-B1 METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES MERCK PATENT GMBH (DE) 2024-06-26 EP claimed
CN-112569162-B Synergistic effect of radix Ophiopogonis extract, amino acid derivative and calcium lactate hydrate 默克专利股份有限公司 2024-04-12 CN claimed
US-11737997-B2 Method to increase cellular availability of calcium in skin cells and mixtures MERCK PATENT GMBH (DE) 2023-08-29 US claimed
US-20220162113-A1 BORATE-GLASS COMPOSITIONS, METHODS OF MANUFACTURE, AND USES THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2022-05-26 US claimed
CN-111315241-B Lactate powder and preparation method thereof 普拉克生化公司 2022-04-26 CN claimed
EP-3947306-A1 BORATE-GLASS COMPOSITIONS, METHODS OF MANUFACTURE, AND USES The Royal Institution For The Advancement Of Learning/McGill University (CA) 2022-02-09 EP claimed
CN-108157932-B Double-screw extrusion mixing and drying-free preparation method of compound food additive lactic acid powder 湖北壮美生物科技有限公司 2021-03-30 CN claimed
CN-112569162-A Synergistic effect of ophiopogon root extract, amino acid derivative and calcium lactate hydrate 默克专利股份有限公司 2021-03-30 CN claimed
US-20200405674-A1 METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES MERCK PATENT GMBH (DE) 2020-12-31 US claimed
EP-3756642-A1 METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES Merck Patent GmbH (DE) 2020-12-30 EP claimed
US-6080715-A Granular compositions of .di-elect cons.-phthalimido peroxyhexanoic acid AUSIMONT S.P.A. (IT) 2000-06-27 US claimed
EP-0852259-A1 Granular compositions of E-phthalimido peroxyhexanoic acid Ausimont S.p.A. (IT) 1998-07-08 EP claimed
EP-0563455-A1 Particulate solid products containing a lump forming inhibitor Purac Biochem B.V. (NL) 1993-10-06 EP claimed
EP-0415567-A2 Composition and method for stabilising organic compounds QUADRANT BIORESOURCES LIMITED (GB) 1991-03-06 EP claimed
EP-0396341-A2 Agglomerated peroxyacid bleach granule and process for making same THE PROCTER & GAMBLE COMPANY (US) 1990-11-07 EP claimed
EP-0353281-A1 METHOD OF DRYING MACROMOLECULES QUADRANT BIORESOURCES LIMITED (GB) 1990-02-07 EP claimed
CN-1037518-A The drying means of macromolecular substance QUADRANT BIORESOURCES LTD (GB) 1989-11-29 CN claimed
WO-1989006976-A1 METHOD OF DRYING MACROMOLECULES QUADRANT BIORESOURCES LIMITED (GB) 1989-08-10 WO claimed
US-4126573-A DIPEROXYAZELAIC ACID OR DIPEROXYDODECANEDIOIC ACID PARTICLES COATED WITH A SURFACTANT THE PROCTER & GAMBLE COMPANY (US) 1978-11-21 US claimed
US-4013773-A VITAMIN E ACETATE OR CLOFIBRATE AND CALCIUM LACTATE HYDRATE YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) 1977-03-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737997-B2 Method to increase cellular availability of calcium in skin cells and mixtures CA2, CHERP, SLC8B1 TP53 211/4885CA1 26/4885CA4 173/4885
US-20200405674-A1 METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES CA2, CHERP, ORAI1 TP53 231/4885CA1 26/4885CA4 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.